Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Erratum

Erratum to: Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers

Authors: Pedro Veliça, Nicholas J Davies, Pedro P Rocha, Heinrich Schrewe, Jonathan P Ride, Chris M Bunce

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Excerpt

It has come to our attention that since publication of our article [1], in the body of the article the term androstenedione has been used in error. The experiments in this study used androstanedione as a test substrate. Androstenedione was not used in any experiments. This error does not in any way invalidate the conclusion of the paper that aldo-keto reductases of the mouse and human 1C-subfamilies lack functional and expression homology. The authors apologise for any confusion caused. …
Literature
1.
Veliça P, Davies NJ, Rocha PP, Schrewe H, Ride JP, Bunce CM: Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers. Mol Cancer. 2009, 8: 121. 10.1186/1476-4598-8-121PubMedCentralCrossRefPubMed
Metadata
Title
Erratum to: Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers
Authors
Pedro Veliça
Nicholas J Davies
Pedro P Rocha
Heinrich Schrewe
Jonathan P Ride
Chris M Bunce
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-21

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue

Research

Uncoupled responses of Smad4-deficient cancer cells to TNFα result in secretion of monomeric laminin-γ2

Research

XIAP gene expression and function is regulated by autocrine and paracrine TGF-β signaling

Research

DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response

Research

Tumor cell-derived PDGF-B potentiates mouse mesenchymal stem cells-pericytes transition and recruitment through an interaction with NRP-1

Research

c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL

Research

Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits